Acumen Pharmaceuticals FY2025 EPS Loss Of $2.00 Vs. Loss Of $1.71 YoY, Cash, Cash Equivalents And Marketable Securities Of $116.9M With Cash Runway Into Early 2027

Benzinga Newsdesk www.benzinga.com Negative 85.1%

Neg 85.1% Neu 0% Pos 0%

Comments

No comments yet. Be the first!